ABMD Abiomed Loading...

From JNJ earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
08:30
Apr 14 ◎
Tim Schmid Executive Vice President, Worldwide Chairman, MedTech, John… JNJ Q1 FY26 call
Abiomed (now JNJ-owned) is experiencing robust growth driven by Impella adoption and positive clinical data, reinforcing JNJ's cardiovascular momentum.
ABMD
HIGH

About ABMD Analyst Coverage

Buzzberg tracks ABMD (Abiomed) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Tim Schmid.